| |
| |
| Catalent Hosts Operation Warp Speed Roundtable at Bloomington, Indiana Site |
|
|
|
| Operation Warp Speed leadership and Catalent recently reviewed the company’s readiness to ship hundreds of millions of COVID-19 vaccine doses for its partner Moderna as soon as possible once authorized by the FDA.
Visitors to Catalent’s facility in Bloomington, Indiana, included Vice President Pence, HHS Secretary Azar, Indiana Governor Holcomb and CDC Director Dr. Redfield, as well as leaders from Moderna and Catalent. During a roundtable session, the group discussed Catalent’s efforts to accomplish this feat including accelerating the construction of a brand-new building, installing and validating new equipment, and hiring over 1,000 new employees for its great team in Indiana. Watch the Roundtable. |
|
| | |
|
|
| |
| Catalent Announces New Partnerships to Advance Cell, Gene and Oncology Treatments |
|
|
|
| At Catalent Cell & Gene Therapy in Maryland, manufacturing operations have commenced to support adeno-associated virus (AAV) production for Passage Bio’s lead gene therapy product candidates for the treatment of rare monogenic disorders of the central nervous system. Also, Catalent announced that it has signed a commercial supply agreement with Blueprint Medicines following FDA approval of GAVRETO™ (pralsetinib). GAVRETO is a new therapy indicated for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. |
|
| | |
|
|
| |
| |
| |
| Catalent Invests $10 Million to Expand High Potency Containment Capabilities For Micronization
The investment will allow flexible jet milling operations of potent and highly potent compounds to be carried out at Catalent’s sites in Malvern, Pennsylvania, and Dartford, U.K. |
|
|
|
| |
| |
| Catalent is Proud to Support Many High-Profile COVID-19 Programs
Catalent has been awarded more than 60 COVID-19-related compounds including antivirals, vaccines, diagnostics and treatments across our biologics, gene therapy, oral technologies, softgel and clinical supply businesses. |
|
|
|
| |
| |
| GPEx® Boost Shortlisted for The Medicine Maker’s Innovation Awards
GPEx Boost builds on Catalent’s proprietary GPEx technology with enhanced benefits, including up to four-fold higher titers in difficult-to-express proteins, reduced ammonia build-up to improve cell growth and viability, and fewer process steps. Vote for GPEx Boost. |
|
|
|
| |
| |
| Catalent Appoints Nakaya Matsumaru as General Manager of its New Clinical Supply Facility in Shiga, Japan
Mr. Matsumaru will head up the 60,000-square-foot facility, which is the latest in Catalent’s expanding Asia-Pacific clinical supplies network. The site will offer extensive services including access to primary and secondary packaging capabilities, Catalent’s FastChain® demand-led supply services, and clinical returns and destruction services. |
|
|
|
| |
| |
| Catalent Included in Fierce Pharma’s List of Top 10 Manufacturers in the Fight Against COVID-19®
In anticipation of what could be multiple successful COVID-19 vaccines in the near future, Fierce Pharma has assembled its list of the top 10 contract manufacturers in the fight against COVID-19. |
|
|
|
| |
| |
| Catalent Completes Acquisition of Cell Therapy Manufacturing Facility from Bone Therapeutics
“Catalent is committed to supporting the development and manufacture of next-generation therapies and bringing life-changing treatments to patients in need,” commented Manja Boerman, Ph.D., President, Catalent Cell & Gene Therapy. |
|
|
|
| |
| |
| Reuters Interviews Catalent Cell & Gene Therapy Expert
Patrick Stragier, Vice President of Operations, Catalent Cell & Gene Therapy discusses the importance of automation in cell and gene therapy manufacturing. |
|
|
|
| |
| |
| BioProcess International Covers Catalent’s Growing Gene Therapy Business
A recently published BioProcess International article includes coverage of Catalent’s recent manufacturing agreements and news of its plans to expand its gene therapy campus in Harmans, Maryland. |
|
|
|
| |
| |
| Virtual Audits in the Time of COVID-19
Due to the travel limitations caused by COVID-19, auditors and their hosts must adapt to a “virtual” or “remote” audit. Featuring the insights of two Catalent experts, a recent PDA Letter article provides insight into virtual audits. |
|
|
|
| |
| |
| Can Pharma Quality Go High Tech?
In a recent article published in Pharmaceutical Technology , two Catalent experts discuss the company’s adoption of technology for audits and customer tours. |
|
|
|
| |
| |
| Catalent Appoints Dr. Behzad Mahdavi as Vice President of Open Innovation
Dr. Mahdavi joins a team of experts that works with customers and external innovators to accelerate the adoption of new development and drug delivery technologies, and scalable manufacturing processes and techniques. |
|
|
|
| |
| Join Our Experts at Live Virtual Events to Hear the Latest on COVID-19 and Technology Development Programs |
|
|
|
| |
| A Catalyst in Drug Development | | Amruta Mhashilkar MD Ph.D., MBA Lead Scientist, St. Petersburg, Florida |
|
|
|
| Dr. Mhashilkar is a Lead Scientist at Catalent’s St. Petersburg, Florida facility. She earned her MD at Grant Medical College, a Master of Public Health and doctorate at the University of South Florida and completed her MBA at Florida Southern College. Dr. Mhashilkar specializes in lipid-based softgel formulation for immediate and extended release. She also works on process development and regulatory CMC support. Find out what drives Dr. Mhashilkar’s passion for softgel formulation - read her published works, which include five peer-reviewed articles. |
|
| | |
|
|
| |
| |
| |
| Biologics
Webinar: “Supply Chain Contingencies to Avoid Upheaval” - This session at the 2020 BIO Investor Forum features Catalent’s Karen Flynn, President of Biologics and Chief Commercial Officer, explaining the challenges and opportunities changing how biomedical supply chains must plan and innovate to continue to serve patients and build resilience. Article: “Control Strategies for Perfusion Cell Culture” - Claudia Berdugo-Davis, Director of Process Development, Catalent Biologics, discusses perfusion in a recent BioPharm International article. Webinar: “Advancing Your Biologics Drug Product: Strategies for Successful Formulation, Tech Transfer and Delivery System” - Learn about formulation development with a focus on stability and aggregation, strategies to accelerate drug product technical transfers, and the trends and usability insights in injection delivery systems. Article: “How COVID-19 is Bending the Curve on Vaccine & Therapeutic Manufacturing Norms” - Bernie Clark, Vice President of Marketing and Strategy, Catalent Biologics, discusses the collaboration and innovation necessary to help combat coronavirus. |
|
| | |
|
|
| Cell & Gene Therapy
Webinar: “CPhI Festival of Pharma Roundtable: Cell & Gene Technology” - Panelists, including Thomas VanCott, Ph.D., Global Head of Product Development, Catalent Cell & Gene Therapy, discuss innovative technologies and their adoption for cell and gene therapies. The panelists consider strategies to improve efficiency and standardization in cell and gene production. Article: “Radiance® Label-Free Monitoring of AAV Transfection in HEK293 Cells Using Laser Force Cytology™” - Catalent and LumaCyte experts compare AAV production with three different transfection reagents using both LumaCyte’s Laser Force Cytology (LFC) instrument, Radiance®, and a digital droplet PCR (ddPCR) based viral genome titer assay. Webinar: “How to Commercially Scale T-Cell Allogeneic Therapies” - Jesse Trekker, Ph.D., Business Development Director at Catalent Cell & Gene Therapy, discusses an innovative manufacturing methodology and fill/finish approaches to accelerate T-cell therapies to the commercial readiness phase. |
|
| | |
|
|
| |
| |
| |
| We are the Catalyst for your Success. Join Us! |
|
|
|
| Catalent ignites the development of their future leaders by continuously investing in our employees and creating an innovative environment to advance their potential. We are growing rapidly across sites in Bloomington, Indiana, Madison, Wisconsin, Winchester, Kentucky, and more.
Visit www.catalent.com/careers for more information. |
|
| | |
|
|
| |
| |
| Every brand has a challenge. We have a solution. | | | | or call +1 877 891 9609 to speak with one of our experts today! | | |
|
|
|
| |
| To unsubscribe or manage your subscriptions, please click here.
For more information call +1-866-720-3148 or in Europe 00800 88 55 6178, email us at sales@catalent.com, or visit our website www.catalent.com. And to learn more about Career opportunities across our global network, visit www.catalent.com/careers. Catalent Pharma Solutions respects your privacy. Links to third party sites are provided as a convenience only. Catalent makes no representation or warranty about the technology, security or any content available at these sites. Links are not intended to imply Catalent's affiliation or endorsement of the website, its owner(s) or the content. © 2020, Catalent Pharma Solutions, Inc. 14 Schoolhouse Road, Somerset, NJ 08873. All rights reserved. |
|
|
|
| |
